From the perspective of physicians and patients, hypoglycemia remains a major limiting factor in effective blood sugar management in diabetes - from initiation to titration to maintenance phase. Fear of hypoglycemia during titration phase erodes patient confidence in his/her insulin and leads to negative treatment experience and finally discontinuation of insulin treatment. Evidence has also indicated that hypoglycemia in the first three months of Basal insulin therapy predicts the risk of hypoglycemia in the long term.
We are pleased to share with you results of the FIRST Head-to-Head Randomized Clinical Trial - the BRIGHT study, comparing insulin Glargine 300 U/mL (ToujeoTM) with insulin Degludec 100 U/mL (IDeg-100), just presented on June 25th, at the ongoing American Diabetes Association Congress, ADA-2018 in Orlando. The key highlights are: Effective & safe titration of insulin is…
